The global kidney cancer drugs market is expected to grow at a healthy rate during the forecast period. Renal Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2% of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.
Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness drives for early detection. This factor is anticipated to bode well for market over the forecast period.
Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate among patients who are mostly diagnosed with RCC during routine checkups for some other medical conditions.
The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel demand for these medicines in the years to come.
Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting product demand. Kidney cancer medicines are one of the life protracting treatment options available for patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is expected to be higher in developed countries compared to developing regions. This factor is expected to impel demand for these medicines from regions like North America and Europe.
However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result, generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct market development in the forthcoming years.
Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in the years to come.
North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive regional growth in the forthcoming years.
The global market is highly consolidated and displays high competition among key participants. Major pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting strategies like collaborations, new product launches, business expansions, and innovation to uphold their market share.
